Pulmonary Function Testing Systems Market - By Product Type (Handheld, Tabletop), By Test Type (Spirometry, Exercise Stress Test), By Application (Chronic Obstructive Pulmonary Disease), By Distribution Channel (Brick & Mortar, E-commerce), By End-use & Forecast, 2023 – 2032
Published Date: August - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationPulmonary Function Testing Systems Market Size
Pulmonary Function Testing Systems Market size was valued at USD 2 billion in 2022 and is estimated to reach USD 3.7 billion by 2032. This significant market growth is primarily attributed to several variables comprising the growing prevalence of lung diseases, the rise in demand for pulmonary function testing, and technological advancements in spirometry diagnostic devices among others.
In developing nations, the prevalence of pulmonary diseases is highest due to socioeconomic status and people living a sedentary lifestyle. This increasing prevalence of lung disease is anticipated to drive market growth globally. Pulmonary disease is one of the leading causes of death globally that in turn leads to the increasing demand for lung diagnostic devices in hospitals and diagnostic centers. Additionally, the severe health concerns associated with respiratory diseases are anticipated to stimulate the demand for testing.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Pulmonary Function Testing Systems Market Size in 2022 | USD 2 billion |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 6.4% |
| 2032 Value Projection | USD 3.7 Billion |
| Historical Data for | 2017 to 2021 |
| No. of Pages | 180 |
| Tables, Charts & Figures | 571 |
| Segments covered | Product, Test Type, Application, Distribution Channel, End-use and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
A pulmonary function testing (PFTs) systems utilizes non-invasive techniques to assess lungs functioning. The tests measure lung volume, capacity, rates of flow, and gas exchange among others. This data can help healthcare professional diagnose and decide the treatment of certain lung disorders.
However, the stringent regulatory framework related to pulmonary function testing systems devices may hamper the market revenue. The U.S. FDA has rigid regulatory compliances and complex approval procedures that may obstruct the pulmonary function testing systems market growth. The majority of pulmonary function testing equipments need a premarket notification, or 510(k) process prior to their commercialization in the market. Such stringent product regulations may lead to penalties and loss of market access in a global marketplace.
Further, regulations majorly delay the approval of these products due to time-consuming documentation and review protocols. These products usually require the optimum level of scrutiny and a set of entire preclinical & clinical reviews through pre-market approvals, with the majority requiring clinical studies and subsequent information. These additional controls include mandates such as post-market surveillance, special labelling requirements, and meeting the pre-set performance standards.
COVID-19 Impact
The COVID-19 arose as an unprecedented public health concern across the globe and has positively impacted the pulmonary function testing systems business growth. The significant demand for COVID-19 diagnosis & treatment had augmented in order to prevent infections due to coronavirus. The usage of lung diseases testing in COVID-19 treatment was rising at a significant pace owing to associated advantages in reducing mortality rates. As per the Johns Hopkins University research studies, around 50% of cases admitted to the intensive care unit required some form of respiratory care.
In order to meet this huge demand, in the U.S. the CDC Strategic National Stockpile (SNS) stored and maintained respiratory care devices that can be utilized on request through suitable networks. The FDA was robustly working to assist surging the availability of respiratory care equipments and accessories for combating the covid-19 pandemic. Further, the World Health Organization (WHO) functioned in association with business players, government bodies, and Pandemic Supply Chain Network among others to boost the production of these products to meet increasing worldwide demand for critically affected and at-risk nations.
Pulmonary Function Testing Systems Market Trends
Increasing incidence of patients suffering from chronic respiratory diseases will primarily drive the market share. Chronic respiratory diseases are one of the leading causes of death across the globe. The disease progression is marked by recurring exacerbations and a steady loss in patients' functional level, culminating in a significant socioeconomic burden. This incremental rise in patient population has substantially increased the hospitalization rate, thereby augmenting the demand for diagnostic products.
Human-Friendly Version Pulmonary function testing (PFT) has become increasingly popular in hospitals and clinics because it helps doctors diagnose and manage respiratory diseases effectively. Conditions like asthma, cystic fibrosis, COPD, and occupational lung diseases have driven up the demand for PFT systems. In the United States alone, an estimated 15 million people had COPD in 2020, a number that's expected to grow in the coming years. This rise in COPD cases is largely due to factors like smoking and poor air quality. As a result, healthcare providers are investing more in PFT systems to better care for patients with these conditions.
Pulmonary Function Testing Systems Market Analysis
Based on product type, the pulmonary function testing systems market is segmented as handheld and tabletop. The handheld pulmonary function testing devices segment held majority market share in 2022 and was valued at over USD 1.2 billion. This segment share is primarily attributed to significant technological advancement and an increase in the awareness of benefits related to the use of portable pulmonary function testing systems. The biggest advantage of a portable devices is that it can remotely monitor the condition and progression of the health of these patients in emergency conditions.
Market players are focusing on commercializing handheld testing products that can monitor multiparameter essential symptoms comprising respiratory rate, heart rate, body temperature, and SpO2. Recently introduced portable spirometer including Respinos is designed in the form of a tube that can be ergonomically inflated by the patient and is integrated with a precise and disposable turbine-based air flow sensor to assess the patient's respiratory condition.
As per the research studies, continuous pulmonary function monitoring can serve as a diagnostic tool for several lung conditions including asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and lung cancer among others. Moreover, according to the American Lung Association, one of the key advantages of this device is that it’s non-invasive as there are no incisions or breaks in patients’ skin and assess every variation that can be the cause of lung disease.
Different types of pulmonary function testing systems are used depending on the specific test needed, like spirometry, lung volume tests, gas diffusion tests, exercise stress tests, high altitude simulations, and others. The spirometry segment is a big deal, worth about 926 million bucks in 2022. This is because spirometers are getting better, tech-wise, and more R&D is being done. Also, people are using non-invasive tests like spirometry more often. The new spirometry testing systems are no longer stuck in one place and rely on volume. Instead, they're portable and flow-based, making them easy to take wherever you need to go. Companies are also working on making spirometers more comfortable and easier to use for patients, based on what each patient needs.
Improving set-up features comprising simple navigation buttons, large on-board display, automatic power on self-test, and lightweight design is assisting in faster operation along with enhanced comfort. Smart spirometers embedded with AI technology can collect data and monitor a patient's condition. As a result, simple, secure and smart spirometers with accurate solutions that help to reduce complexity and shorten the path to diagnosis will expand the market size.
Let's talk about how different lung problems affect the market for machines that check how well your lungs are working. There are different types of lung problems, like COPD (short for "chronic obstructive pulmonary disease"), asthma, feeling out of breath all the time, and scarring of the lungs (called pulmonary fibrosis). From all these, asthma is a big one. In 2022, more than 25% of the money spent on these machines was for asthma testing. And we think it will stay that way for a while. Why? Because more and more people have asthma, and doctors prefer to use fancy new tests to check their lungs. People with asthma often have other allergies, like eczema (a skin condition) or hay fever (a reaction to pollen). The National Institute of Health says that around 300 million people worldwide had asthma in 2022. That's a lot of people!
Spirometry is the recommended test to confirm asthma. It measures the amount of air patient able to breathe in and out and its rate of flow. Moreover, benefits associated with testing such as reliability in disease screening and reduced severity of infection with a better diagnosis are forecasted to positively impact the industry growth.
Based on distribution channel, the pulmonary function testing systems market is segmented as the hospital & clinics pharmacies, brick & mortar, and e-commerce. The brick & mortar stores segment is estimated to progress at substantial growth rate to reach over USD 1.6 billion by 2032. This substantial segment share is owing to several advantages offered by the medical retail stores in medical diagnostic devices distribution including the availability of a wide array of products and substantial discounts.
Additionally, various market players are focusing on marketing products through medical retail stores that increase the salability of a wide variety of product, thus propelling segment landscape. Some medical retail stores also offer educational programs for precise product awareness and focus on combating health issues including lung diseases, etc. Moreover, well-defined safety, effective services, and security policies are boosting the segment revenue.
Based on end-use, the pulmonary function testing systems market is segmented diagnostic centers, homecare settings, and others. The hospitals & clinics segment is projected to reach more than USD 1.7 billion by 2032. The soaring use of novel portable pulmonary function testing devices in hospital settings delivering rapid and reliable outcomes is estimated to surge the patient preference for these healthcare facilities. The availability of a broad spectrum of pulmonary function tests that supports continuous monitoring with proven accuracy is set to drive product preference in hospitals & clinics.
Growing admissions with lung ailments and growing disease screening initiatives along with the accessibility to board-certified healthcare professionals are some other variables that are augmenting the segment growth positively. Furthermore, the rising disease burden in developed economies with enhanced healthcare infrastructure is projected to stimulate the diagnosis & treatment rate at hospitals.
The U.S. pulmonary function testing systems market is anticipated to exceed USD 1.6 billion by 2032. This majority market share is credited to several factors such as the presence of major industry players, an upsurge in the demand for respiratory diseases continuous monitoring services, rise in the prevalence of lung diseases conditions, and growing number of hospital admissions across the country among others. As per the American Lung Association data 2021, around 236,000 people were diagnosed with lung cancer in the U.S.
Additionally, according to the Asthma and Allergy Foundation of America, currently, around 26 million people in the U.S. have asthma. These adverse events are anticipated to upsurge the adoption rate of pulmonary function testing systems devices for better disease management. This is further driving the entry of new players in the market that are projected to increase over the forecast timeframe.
Pulmonary Function Testing Systems Market Share
Some of the major market players operating in the pulmonary function testing systems industry are
- Koninklijke Philips N.V.
- Medical Equipment Europe
- Medtronic
- Minato Holdings Inc
- Morgan Scientific Inc
- ndd Medizintechnik AG
Major market players are adopting strategic formulations such as forward integration, new product development, geographical expansion, and research collaborations to garner maximum industry share and promote company growth.
Pulmonary Function Testing Systems market News
- In January 2021, NuvoAir announced the partnership with Roche to make its technology available in selected cystic fibrosis (CF) centers. NuvoAir’s platform has been developed for patients to conduct lung function assessments at home. This strategic move assisted the company in bolstering its product portfolio and offered a competitive edge.
- In August 2019, Resmed completed the acquisition of HB Healthcare that provides home medical equipment such as sleep and respiratory care devices to the patients. This acquisition helped the company to enhance their product portfolio in mechanical ventilators and increase their market value thereby enhancing their business revenue.
Pulmonary function testing systems market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD (million) and volume (units) from 2018 to 2032 for the following segments
Click here to Buy Section of this Report
By Product Type, 2018 - 2032 (USD Million & Units)
- Handheld
- Tabletop
By Test Type, 2018 - 2032 (USD Million)
- Spirometry
- Lung Volume Test
- Gas Diffusion Test
- Exercise Stress Test
- High Altitude Simulation Testing
- Others
By Application, 2018 - 2032 (USD Million)
- Chronic Obstructive Pulmonary Disease
- Asthma
- Chronic Shortness of Breath
- Pulmonary Fibrosis
- Others
By Distribution Channel, 2018 - 2032 (USD Million)
- Hospital & clinics pharmacies
- Brick & Mortar
- E-commerce
By End-use, 2018 - 2032 (USD Million)
- Hospitals & Clinics
- Diagnostic Centers
- Homecare Settings
- Others
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Poland
- Sweden
- The Netherlands
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Indonesia
- Philippines
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Chile
- Peru
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Iran
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy